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Introduction: We evaluated the safety of current treatment regimens for patients with RA and HBV in a large US cohort.
Methods: We identified biologic and nonbiologic treatment episodes of RA patients using 1997 to 2011 national data
from the US Veterans Health Administration. Eligible episodes had evidence of HBV infection (HBV surface antigen, HBV
core antibody, HBV e-antibody and/or HBV DNA) and had a baseline alanine aminotransferase (ALT) <1.5 times the upper
limit of laboratory normal within 90 days prior to initiation of a new biologic or nonbiologic DMARD. The main outcome
of interest was hepatotoxicity, defined as ALT elevation >100 IU/mL. Results were reported as the cumulative incidence
of treatment episodes achieving hepatotoxicity at 3, 6 and 12 months post biologic exposure.
Results: Five hundred sixty-six unique RA patients with HBV contributed 959 treatment episodes. Mean age was 62.1 ±
10.3 years; 91.8% were male. Hepatotoxicity was uncommon, with 26 events identified among 959 episodes (2.7%) within
12 months. Hepatotoxicity was comparable between biologic and nonbiologic DMARDs (2.6% vs. 2.8%, P = 0.87). The
median time between HBV screening and starting a new RA drug was 504 days (IQR 144, 1,163). Follow-up HBV testing
occurred among 14 hepatotoxicity episodes (53.8%) at a median of 202 days (IQR 82, 716) from the date of ALT elevation.
A total of 146 (15.2%) treatment episodes received at least one test for HBV DNA at any point in the observation period.
Conclusions: Among US veterans with RA and HBV the risk of hepatotoxicity is low (2.7%), and comparable between
biologic and nonbiologic DMARDS (2.8% vs. 2.6%, P = 0.87). HBV testing associated with DMARD initiation or
hepatotoxicity was infrequent.Introduction
Treatment for rheumatoid arthritis (RA) may present
unique risks to patients who are also chronically infected
with hepatitis B virus (HBV). Agents associated with acute
liver injury, such as leflunomide, may be more difficult to
tolerate in this setting [1]. Biologic agents and oral gluco-
corticoids alter host immune responses to HBV infection,
which may increase HBV replication with resultant hep-
atocyte necrosis, a clinical phenomenon known as HBV* Correspondence: Mary.burton2@va.gov
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unless otherwise stated.reactivation [2]. Other agents, such as methotrexate, can
cause additive injury over time even in the absence of ele-
vated liver enzyme tests [3].
The sparse literature regarding the safety of current
treatments for RA in patients with HBV yields conflicting
results. Several case reports document fulminant hepatic
failure in RA patients with HBV who were prescribed bio-
logic agents, as well as in patients prescribed traditional
disease-modifying antirheumatic drugs (DMARDs) [4-6].
In contrast, small prospective European studies (<100 pa-
tients) suggest low to absent risk for hepatotoxicity with
biologic DMARDs in patients with rheumatic disease and
HBV [7-10]. However, small prospective Asian studies
demonstrate increased risk for HBV reactivation withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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case-control analysis of the Food and Drug Administration
(FDA) Adverse Event Reporting System database found an
increased risk of adverse event reporting among patients
with RA and HBV who received rituximab, methotrexate
and/or oral glucocorticoids and raised concerns regarding
increased risk for hepatotoxicity with simultaneous use of
multiple DMARDs in these patients [6].
Despite growing concerns regarding appropriate man-
agement of viral hepatitis in the setting of RA treatments,
the optimal screening for HBV in RA patients is an unset-
tled issue [13]. Current American College of Rheumatol-
ogy (ACR) recommendations limit screening to patients
with HBV risk factors before prescribing methotrexate
or leflunomide [14]. Some experts recommend routine
screening prior to the initiation of biologic agents, as well
as methotrexate and leflunomide [2]. The FDA recently
recommended screening all patients for HBV infection
prior use of rituximab [15]. The Centers for Disease Con-
trol and Prevention (CDC) advocates routine screening
for HBV prior to immunosuppression in all patients [16].
Given the lack of consensus regarding the safety of
current treatment regimens for RA in patients with
HBV as well as best practices regarding screening for
this viral infection, it is important to examine screening
practices and outcomes in large registries of RA patients.
Herein, we assessed the development of hepatotoxicity
and the laboratory evaluation by RA providers to detect




We conducted a retrospective cohort study using electronic
health record data from the Veterans Affairs Informatics
and Computing Infrastructure [17], linked to administrative
data from the Veterans Health Administration Decision
Support System from 1997 to 2011. Eligible patients
qualified to be in the cohort after they had at least one
diagnosis of RA (International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) code:
714.X) from a rheumatology provider between October 1,
1997 and December 31, 2011 and a prescription for at least
one biologic or nonbiologic DMARD between October 1,
2001 and September 30, 2011. VA prescription data was
not available until fiscal year 2002. DMARDs of interest
included methotrexate, sulfasalazine, leflunomide, and
hydroxychloroquine. Biologics included etanercept, inflixi-
mab, adalimumab, rituximab, and abatacept. For compari-
sons among biologics, we grouped etanercept, infliximab,
adalimumab as anti-tumor necrosis factor agents (TNFs).
Newer TNFs (for example certolizumab, golimumab) and
other biologics (that is tocilizumab) were not used fre-
quently enough to allow for inclusion in this study.Furthermore, we required laboratory evidence of prior
HBV infection, defined as a positive result for any of the
following serologic markers prior to the start of follow-
up: HBV surface antigen (HBsAg), HBV core antibody
(HBcAb), HBV e-antigen (HBeAg), and HBV DNA. At
the start of follow-up, termed the ‘index date’, which was
anchored at new initiation of a DMARD or biologic, pa-
tients must have had a normal or near-normal serum
alanine aminotransferase (ALT) level (<1.5 times the
upper limit of normal for clinical laboratory monitoring,
or 66 IU/ml) measured within the preceding 90 days.
National datasets using similar parameters had >95%
specificity at excluding American males with significant
liver disease [18].
Finally, because the presence of, or treatment for, human
immunodeficiency virus (HIV) infection or a hematologic
malignancy might affect the risk for hepatotoxicity in pa-
tients with concomitant HBV and yield confounding,
patients with an ICD-9 code for HIV infection (042.XX)
and/or hematologic malignancy (200–208.92) within one
year prior to the index date were excluded from the main
analysis. However, to maximize generalizability, these pa-
tients were included as part of a sensitivity analysis.
Exposure and outcome assessment
Each drug-specific index date defined a treatment episode.
Patients who initiated different therapies could contribute
more than one treatment episode. Current exposure was
considered as-treated based upon days’ supply (pills or sy-
ringes dispensed) or usual dosing intervals (infused bio-
logics). For rituximab, exposure was assumed to extend 12
months after each infusion. Exposure was extended by 90
days after the end of days’ supply or the usual dosing inter-
vals for all other therapies.
The outcome of interest was hepatotoxicity, which was
defined as an increase in serum ALT to greater than
100 IU/mL, corresponding to approximately a threefold
elevation of population normal levels for males [19,20].
A threefold or greater elevation of ALT has been previ-
ously used to identify clinically significant liver enzyme
elevation in the setting of viral hepatitis reactivation as
well as drug toxicity [21-23]. Suspected cases of hepato-
toxicity where confirmed manually by an infectious dis-
ease specialist’s review of medical records and assessed
for diagnosis of liver failure, hepatic encephalopathy,
liver transplant or death within 90 days of the first date
of ALT elevation. The cause of death was determined by
corresponding death note or diagnosis upon discharge
to hospice care.
Covariates
Covariates were selected based on potential contribution to
hepatotoxicity in patients with RA informed by review of
the literature [3]. These covariates included demographics,
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infection, solid cancer), and other medications used for
arthritis (for example oral glucocorticoids). The 12-month
period preceding each index date defined the baseline
period for assessment of most covariates, except for con-
comitant medication use, (six months preceding the index
date). Comorbid conditions were characterized using
ICD-9 codes from provider diagnoses.
Statistical analysis
Hepatotoxicity was examined in the first one year after
treatment initiation. The risk of hepatotoxicity for each
drug treatment was reported as a cumulative incidence and
quantified as the proportion of patients that met the pri-
mary outcome within three, six and twelve months after
the index date. Drug-specific comparisons were made using
patients receiving sulfasalazine and/or hydroxychloroquine
without biologics, methotrexate or leflunomide, which was
the referent group. Two-by-two tables were constructed to
examine the effect of baseline covariates on hepatotoxicity.
Statistical comparisons were made using chi-square or
Fisher’s exact test where appropriate. Covariates with cen-
tral tendency were presented as mean ± standard deviation;
those not showing central tendency were measured using
interquartile range (IQR).
HBV laboratory screening practices were examined de-
scriptively by plotting the kernel density function of the
distribution of time between each treatment episode’s
index date and any HBV-related laboratory test. Separate
plots were created for laboratory tests before and after
the index date, and results were stratified by presence or
absence of hepatotoxicity. The purpose of these plots
was to descriptively assess the provider’s testing for HBV
before initiation of new RA therapies and after treatment
when hepatotoxicity was identified. Analyses were per-
formed using SAS 9.2 (SAS Institute, Cary, NC, USA).
Ethical approval
This study received approval from Institutional Review
Boards of the Birmingham VAMC and the G.V. Sonny
Montgomery VAMC. Informed consent was not required
given the study design.
Results
Cohort description
A cohort of 38,453 patients with RA was identified, from
which a total of 566 unique patients contributed 959 treat-
ment episodes (Figure 1; Table 1). Mean age was 62.1 ± 10.3
years; 91.8% of the cohort was male. The most common co-
morbid diagnoses were hypertension (62.3%) and diabetes
mellitus (21.9%); 15.1% were co-infected with hepatitis C.
A total of 650 nonbiologic DMARD treatment epi-
sodes and 309 biologic treatment episodes were identi-
fied (abatacept 27, rituximab 24, TNFs 258). HBcAb wasidentified in 827 treatment episodes (86.2%). Detectable
HBsAg, HBeAg, and HBV DNA were present in 124
(12.6%), 105 (10.9%) and 28 (2.9%) of all episodes, re-
spectively (episodes could have >1 of these laboratory
tests). Over half of the treatment episodes also had de-
tectable HBsAb (531, 55.4%).
The majority (89%) of TNF use was etanercept (113
episodes) and adalimumab (116 episodes). Over half of
biologic treatment episodes (58%) were also prescribed
concomitant methotrexate or leflunomide within the
preceding six months. The prevalence of baseline gluco-
corticoid use was 36.2%. HBV antiviral prescription oc-
curred either before or within six months of the index
date for 23 treatment episodes (2.4%). Of these, the ma-
jority of HBV antiviral prescriptions occurred in cases
with a detectable HBsAg (21/23, 91.3%); antiviral pre-
scription was associated with a detectable HBsAg (21/
124 + HBsAg vs. 2/835 -HBsAg, P = 0.001). Lamivudine
was the most commonly prescribed HBV antiviral (13/23
episodes, 56.5%). Tenofovir was prescribed in two epi-
sodes (8.7%), adefovir and entecavir were each pre-
scribed in four episodes (17.4%).
Outcome
Of 959 treatment episodes, 26 (2.7%) met the definition of
hepatotoxicity (Table 2) occurring among 25 unique pa-
tients. Hepatotoxicity was comparable between biologic
and nonbiologic DMARDs, with eight episodes identified
among the biologics and 18 among traditional DMARDs
(2.6% vs. 2.8%, P = 0.87). Among biologics, hepatotoxicity
occurred in 1/24 rituximab (4.2%), 2/27 abatacept (7.4%)
and 5/258 (1.9%) TNF treatment episodes. There was no
statistically significant increased risk of hepatotoxicity for
any drug-specific comparisons. Based upon medical rec-
ord review of the 26 cases of hepatotoxicity, there were no
cases of liver failure, hepatic encephalopathy or liver trans-
plant. Four deaths were noted, three attributed to infec-
tious causes and one to metastatic bladder cancer.
More hepatotoxic events were detected the first three
months after treatment initiation (n = 13) than months 3
to 6 (n = 7) or 6 to 12 (n = 6). Although the majority of
hepatotoxic events (n = 20, 77%) were detected in the
first six months of therapy, event rates for hepatotoxicity
were similar between months 0 to 6 and months 6 to 12
(20/1369, 1.4% vs. 6/496, 1.2%). Based upon the sensitiv-
ity analysis that removed the restriction for various dis-
eases, HIV infection (P = 0.008), hematologic malignancy
(P = 0.006), HBV antiviral prescription (P = 0.002) and
oral glucocorticoid use (P = 0.015) were significantly as-
sociated with hepatotoxicity (Table 3).
HBV screening practices
The median time between a preceding test for any HBV
laboratory markers and DMARD initiation was 504 days
Figure 1 Flow diagram illustrating cohort selection. Index date refers to the date a new DMARD was initiated. DMARD, disease-modifying antirheumatic
drugs; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; HBeAg, hepatitis B e-antigen; HBV DNA, hepatitis B DNA.
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testing for any HBV laboratory markers occurred infre-
quently, with no observable difference between patients
who experienced hepatotoxicity and those who did not
(Figure 3). Among 26 episodes of hepatotoxicity, order-
ing of any HBV laboratory testing occurred in 14 cases
(53.8%), at a median of 202 days (IQR 82, 716) from the
date of hepatotoxicity to the date the first HBV test was
ordered. In patients who did not experience hepatotox-
icity, ordering of any HBV laboratory testing occurred in
342 episodes (36.7%), with a median of 494 days (IQR
162, 991) between DMARD initiation and HBV labora-
tory monitoring. Of the entire cohort, paired testing of
HBV DNA occurred prior to DMARD initiation and
during follow-up in only 35 instances (3.6%). A total of
146 (15.2%) treatment episodes received at least one test
for HBV DNA at any point in the observation period.Discussion
This study explored hepatotoxicity in a real-world cohort
of RA patients with chronic HBV infection and is among
the largest studies to date of RA patients with HBV. Our
results show that the overall rate of hepatotoxicity with
conventional therapies for RA is low, even for patients
with risks for HBV reactivation. In addition, risk of hep-
atotoxicity was relatively comparable between DMARDs
and biologic agents. Among biologics, hepatotoxicity was
somewhat more frequent in non-TNFs than TNFs but the
difference was not statistically significant. We detected the
majority of hepatotoxic events during the initial three
months after beginning RA medications. Testing for HBV
or HBV reactivation in relation to DMARD or biologic
initiation or hepatotoxicity events was infrequent.
Our study is unique in that it examined the safety of
RA treatments among the full spectrum of chronic HBV
Table 1 Patient characteristics measured at the start of each medication treatment episode
Baseline covariates (%) ABA ADA ETA INF LEF MTX RIT SSZ-HCQ Total
(N = 27) (N = 116) (N = 113) (N = 29) (N = 110) (N = 183) (N = 24) (N = 357) (N = 959)
Unique patients 25 113 112 26 98 170 18 302 566
Mean age, years (SD) 60.5 (8.2) 61.0 (9.9) 61.2 (9.7) 57.1 (9.4) 64.5 (11.0) 62.2 (10.6) 62.2 (7.7) 62.3 (10.5) 62.1 (10.3)
Male gender 25 (92.6) 106 (91.4) 108 (95.6) 23 (79.3) 101 (91.8) 167 (91.3) 23 (95.8) 327 (91.6) 880 (91.8)
Medication use six months prior start of treatment episode
MTX/LEF 18 (66.7) 71 (61.2) 69 (61.1) 20 (69.0) 51 (46.4) 17 (9.3) 12 (50) 145 (40.6) 403 (42.0)
HCQ/SSZ 4 (14.8) 18 (15.5) 19 (16.8) 4 (13.8) 21 (19.1) 68 (37.2) 3 (12.5) 45 (12.6) 182 (19.0)
Oral glucocorticoids 9 (33.3) 43 (37.1) 50 (44.3) 8 (27.6) 39 (35.5) 68 (37.2) 13 (54.2) 117 (32.8) 347 (36.2)
HBV antivirals1 1 (3.7) 5 (4.3) 2 (1.8) 0 (0) 0 (0) 3 (1.6) 0 (0) 12 (3.4) 23 (2.4)
Comorbidities2
Hepatitis C 5 (18.5) 18 (15.5) 23 (20.4) 7 (24.1) 6 (5.5) 11 (6.1) 6 (25.0) 69 (19.3) 145 (15.1)
COPD 4 (14.8) 13 (11.2) 19 (16.8) 8 (27.6) 20 (18.2) 5 (19.1) 7 (29.2) 65 (18.2) 171 (17.8)
Hypertension 15 (55.6) 65 (56.0) 65 (57.5) 14 (48.3) 76 (69.1) 112 (61.2) 14 (58.3) 236 (66.1) 597 (62.3)
Diabetes mellitus 4 (14.8) 22 (19.0) 19 (16.8) 2 (6.9) 19 (17.3) 50 (27.3) 4 (16.7) 90 (25.2) 210 (21.9)
Solid cancer 2 (7.4) 6 (5.2) 5 (4.4) 2 (6.9) 17 (15.5) 21 (11.5) 2 (8.3) 31 (8.7) 86 (9.0)
1HBV antivirals - lamivudine, entecavir, tenofovir, telbivudine, adefovir, emtricitabine, emtricitabine/tenofovir; 2defined by International Classification of Diseases,
Ninth Revision (ICD-9) codes and measured 12 months prior to the index date. ABA, abatacept; ADA, adalimumab; ETA, etanercept; INF, infliximab; LEF,
leflunomide; MTX, methotrexate; RIT, rituximab; SSZ-HCQ, sulfasalazine/hydroxychloroquine; SD, standard deviation; HBV, hepatitis B virus; COPD, chronic
obstructive pulmonary disease.
Burton et al. Arthritis Research & Therapy  (2015) 17:136 Page 5 of 9infection, including HBV carriers, resolved HBV infection
and isolated HBcAb. HBV carriers retain HBsAg and have
increased risk for hepatotoxicity with RA medications
when compared to other chronic HBV states [24]. Patients
who have HBsAb in addition to HBcAb have ‘resolved’






Episodes in which any
occurred during follow
0-3 month (%)Ϯ 3-6 m
Biologic agents 309 8 271 201
Abatacept 27 2 (7.4) 24 (88.9) 21 (77
Adalimumab 116 2 (1.7) 103 (88.8) 77 (66
Etanercept 113 3 (2.7) 92 (81.4) 70 (61
Infliximab 29 0 (0) 28 (96.6) 18 (62
Rituximab 24 1 (4.2) 24 (100) 15 (62
Nonbiologic agents 650 18 524 373
Leflunomide 110 3 (2.7) 93 (84.5) 71 (64
Methotrexate 183 8 (4.4) 163 (89.1) 113 (6
Sulfasalazine-
Hydroxychloroquine
357 7 (2.2) 268 (75.1) 189 (5
TOTAL (% of total
episodes)
959 26 (2.7) 795 (82.9) 574 (5
*Hepatotoxic events in time period divided by treatment episodes for drug listed in
follow-up time period. Summation of three columns will exceed the total episodes,
censuring occurred (failure or end of follow-up period). ŦEvent rate percentage equ
of ALT tests performed in same time period for drug row. ALT, alanine aminotransfeconventional RA treatments. Isolated HBcAb (absence of
HBsAb and HBsAg) can signify occult HBV infection, with
continued viral replication at low levels in serum or liver
tissue [25]. Current ACR guidelines do not address appro-
priate management of patients with isolated HBcAb [26].
Some experts recommend testing for HBV DNA in thisd among treatment episodes
ALT testing
-up period
Event rates for hepatotoxicity






179 4 3 1
.8) 18 (66.7) 0 (0) 1 (4.8) 1 (5.6)
.4) 74 (63.8) 1 (1.0) 1 (1.3) 0 (0)
.9) 65 (57.5) 2 (2.2) 1 (1.4) 0 (0)
.1) 14 (48.3) 0 (0) 0 (0) 0 (0)
.5) 8 (33.3) 1 (4.2) 0 (0) 0 (0)
317 9 4 5
.5) 50 (45.5) 1 (1.1) 1 (1.4) 1 (2.0)
1.7) 103 (56.3) 3 (1.8) 1 (0.9) 4 (3.9)
2.9) 164 (45.9) 5 (1.9) 2 (1.1) 0 (0)
9.9) 496 (51.7) 13 (1.6) 7 (1.2) 6 (1.2)
row; Ϯrepresents episodes that had at least one ALT test performed in given
since an ALT could be performed in all three follow-up periods, unless
als the number of hepatotoxicity events in time period divided by the number
rase.
Table 3 Effect of baseline covariates on hepatotoxicity in cohort (including HIV infection and hematologic malignancy,
n = 1,007)
Covariate* Covariate present Covariate absent P valueϮ
Treatment episodes Hepatotoxic episodes (%) Treatment episodes Hepatotoxic episodes (%)
Hepatitis C§ 158 8(5.1) 849 26(3.1) 0.201
HIV infection§ 25 4(16.0) 982 30(3.1) 0.008
Hematologic malignancy§ 23 4(17.4) 984 30(3.1) 0.006
HBV antiviral prescription¶ 29 5(17.2) 978 29(3.0) 0.002
Oral glucocorticoid prescription¶ 364 19(5.2) 643 15(2.3) 0.015
Statin prescription¶ 364 11(3.0) 643 23(3.6) 0.64
*Defined within 12 months of index date unless otherwise specified; Ϯchi-square or Fisher’s exact test; §defined by International Classification of Diseases, Ninth
Revision (ICD-9) codes 070.41, 070.44, 070.51, V0262 (hepatitis C), 042.XX (HIV infection), 200–208.92 (hematologic malignancy); ¶prescription within six months of
index date. HIV, human immunodeficiency virus.
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more frequent laboratory monitoring and/or antiviral
treatment [27].
The observed rate of hepatotoxicity (ALT >100 IU/
mL) in our RA cohort of HBV carriers, isolated HBcAb
and resolved HBV infection was 1.9% within 12 months
of biologic and nonbiologic DMARD initiation, with no
serious liver-related sequelae (death, hospitalization, liver
transplant) reported as a consequence of treatment for
RA. Although the varying cohort compositions, defini-
tions of hepatotoxicity and study duration limit compari-
son to previously published studies, our low observed
rate of hepatotoxicity is reassuring.
In contrast, a retrospective study from Korea reported a
15.9% rate of hepatotoxicity (defined as ALT ≥2 ULN onFigure 2 Testing of HBV markers before the index date. Distribution of day
surface antigen, hepatitis B core antibody, hepatitis B e antigen, HBV DNA) p
or absence of hepatotoxicity. (ALT>100 IU/mL). Y axis represents a probabili
at each time point.two consecutive tests) in 88 patients with inflammatory
arthritis with isolated HBcAb treated with TNFs ( average
follow-up period 24.7 ± 16.4 months after TNF initiation)
[28]. A prospective report of Italian rheumatic disease pa-
tients found that 34/67 (50.7%) isolated HBcAb-positive
patients experienced ALT elevation of ≥2 ULN at a me-
dian of 12 months after initiating TNFs in combination
with nonbiologic DMARDS (methotrexate, prednisone
and/or nonsteroidal anti-inflammatory drugs) [28,29]. No
deaths or serious adverse events related to HBV were re-
ported in either study [28,29].
Many studies examining the safety of RA treatments in
patients with chronic HBV assess the risk of HBV reactiva-
tion, which is characterized by abrupt increases in serum
levels of HBV DNA followed by increased transaminasess (x-axis) between the testing of any HBV laboratory marker (hepatitis B
rior initiation of a new DMARD (index date), stratified by the presence
ty density function that any hepatitis B laboratory marker was ordered
Figure 3 Testing of HBV markers after the index date. Distribution of days (x-axis) between testing of any HBV laboratory marker (hepatitis B
surface antigen, hepatitis B core antibody, hepatitis B e antigen, HBV DNA) after initiation of a new DMARD (index date), stratified by the presence
or absence of hepatotoxicity. (ALT>100 IU/mL). Y axis represents a probability density function that any hepatitis B laboratory marker was ordered
at each time point.
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patients with RA are believed to be asymptomatic, severe
cases of hepatitis that progress to fulminant hepatic failure
and death are reported [30]. A recent systematic review of
122 patients estimated that 12.3% of HBsAg-positive pa-
tients receiving TNF and/or DMARD therapy experience
HBV reactivation [24]; small prospective studies (<100 pa-
tients) estimate HBV reactivation rates of 0 to 5% in
HBcAb-positive patients without HBsAg [29]. We could
not fully assess for HBV reactivation in our cohort given
the infrequent testing of HBV DNA by the treating rheu-
matologists. Given the low rate of ALT elevation observed,
we suspect the rate of clinically significant HBV reactiva-
tion was low.
Antiviral prophylaxis is recommended in patients with
detectable HBsAg prior to immunosuppression [2]. The
evidence for this recommendation stems from studies of
HBV patients receiving cytotoxic chemotherapy; how-
ever, small studies have suggested a benefit of antiviral
prophylaxis in RA patients with detectable HBsAg [31].
In our cohort, treatment episodes prescribed HBV anti-
virals were more likely to experience hepatotoxicity than
those who were not (5/29 (17.2%) vs. 29/978 (3.0%)). We
hypothesize that treatment episodes with increased risk
for hepatotoxicity were more likely to receive HBV anti-
virals, as a detectable HBsAg was associated with HBV
antiviral prescription.
Among our cohort, screening for HBV in conjunction
with DMARD initiation infrequently occurred. Themedian time between RA treatment initiation and test of
any HBV marker (HBsAg, HBcAb, HBeAg, HBV DNA)
was 504 days. Testing of any HBV laboratory marker oc-
curred only in roughly one-third of treatment episodes
(36.7%) in which hepatotoxicity did not occur. As almost
half (55.4%) of treatment episodes demonstrated detect-
able HBsAb, it is possible providers may have perceived
a low risk for hepatotoxicity. However, testing for HBV
in conjunction with hepatotoxicity was also infrequent.
A follow-up HBV test (HBsAg, HBcAb, and/or HBeAg)
was ordered in only just over half of hepatotoxicity epi-
sodes (53.8%), with a median time of 202 days from the
ALT elevation to performance of any HBV test. This low
level of HBV testing likely reflects a limited understanding
of appropriate screening and monitoring for HBV infec-
tion by providers. In a recent survey of US rheumatolo-
gists, 92% of respondents said that they utilized HBsAg for
HBV screening but only 54% and 7% ordered HBcAb and
HBV DNA, respectively [13]. In this same report, universal
screening for HBV prior biologic initiation was affirmed in
69% but dropped to 7% prior any prescription of oral glu-
cocorticoids [13].
Previous publications have suggested increased risks
for hepatotoxicity with biologic DMARDS compared to
other RA treatments [12,32]; however, we did not detect
any significant difference in hepatotoxicity between bio-
logic and nonbiologic DMARDS. As expected, metho-
trexate and leflunomide had the numerically highest risk
for hepatotoxicity. We did find that hematologic
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associated with the development of hepatotoxicity. Many
medications, including those used for cancer and HIV,
have strong associations with hepatotoxicity [33-35].
There are limitations to our study. Cohort entry re-
quired laboratory detection of an HBV marker, which
would not detect episodes where chronic HBV infection
was discovered only in the event of hepatotoxicity. Our
follow-up period was limited to 12 months after DMARD
initiation. HBV reactivation has been reported >2 years of
beginning treatment for RA and upon cessation of im-
munosuppressive medications [33,36]; thus we may have
missed later occurring episodes. However, our focus on
this early time period was intended to capture the most
probable interval in which safety problems could be de-
tected. We used a stringent definition of hepatotoxicity
(ALT >100 IU/mL) based upon laboratory criteria, which
may overestimate clinical risk with these medications
given that no serious medical sequelae ensued. In addition,
the infrequent monitoring of HBV DNA did not allow us
to distinguish ALT elevations as HBV reactivation. We
could only review the records of care within the VHA
health care system. We cannot exclude the possibility that
some patients may have had monitoring performed, hep-
atotoxicity detected, and received treatment for HBV by
outside providers. Lastly, our cohort was largely com-
prised of older US males with RA and may not be
generalizable to other RA populations.
Conclusions
We report a low rate of hepatotoxicity among a large co-
hort of US veterans with RA and HBV infection who
were prescribed conventional RA therapies. We found
comparable rates of hepatotoxicity between biologic and
nonbiologic DMARDS. Screening for HBV in conjunc-
tion with DMARD initiation and/or at the time of iden-
tified hepatotoxicity, was infrequent.
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